BrainsWay Ltd. (NASDAQ:BWAY) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET

Company Participants

Bob Yedid – LifeSci Advisors

Christopher von Jako – President and Chief Executive Officer

Scott Areglado – Chief Financial Officer

Conference Call Participants

Steve Lichtman – Oppenheimer

Jayson Bedford – Raymond James

Jeffery Cohen – Ladenburg Thalmann

Raghuram Selvaraju – H.C. Wainwright

Jason Wittes – Loop Capital

Operator

Good morning, and welcome to BrainsWay Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this call is being recorded.

I would now like to turn the conference over to your host, Bob Yedid. Please go ahead, sir.

Bob Yedid

Thank you, and welcome to BrainsWay’s second quarter 2022 earnings conference call. With us today are BrainsWay’s President and Chief Executive Officer, Christopher von Jako; and Chief Financial Officer, Scott Areglado. The format for today’s call will be a discussion of recent trends and business updates from Chris, followed by a detailed discussion of the financials from Scott. Then we will open up the call for your questions. Earlier today, BrainsWay released financial results for the three and six months June 30, 2022. Copy of the press release is available on the company’s Investor Relations website.

Before I turn the call over to Chris and Scott, I would like to remind you that on this conference call, including both management’s prepared remarks and the question-and-answer session may contain projections or other forward-looking statements regarding among other topics, BrainsWay’s anticipated future operating and financial performance, business plans and prospects and expectations for its products and pipeline, which are all subject to risk and uncertainties, including shifting market conditions, resulting from the COVID-19 pandemic, the global supply chain crisis, as well as the use of non-GAAP financial information.

Additional information regarding these and other risks are available in the company’s earnings release and its filings with the SEC, including the risk factors section contained in BrainsWay’s Form 20-F.

With those remarks, it’s my pleasure to turn the call over to Chris von Jako, CEO. Chris?

Christopher von Jako

Thank you, Bob. Welcome, everyone, and thank you for joining us today. To begin, we recorded solid second quarter results in the face of headwinds caused by the macroeconomic challenges impacting existing and potential new customers. The company has made progress in Q2 with achievements on the commercial, clinical, regulatory and reimbursement fronts.